AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans

YM Loo, PM McTamney, RH Arends, RA Gasser Jr… - Medrxiv, 2021 - medrxiv.org
Despite the success of SARS-CoV-2 vaccines, there remains a need for more prevention
and treatment options for individuals remaining at risk of COVID-19. Monoclonal antibodies …
被引用次数：35 相关文章

AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans

YM Loo, PM McTamney, RH Arends, RA Gasser… - medRxiv, 2021 - medrxiv.org
Despite the success of SARS-CoV-2 vaccines, there remains a need for more prevention
and treatment options for individuals remaining at risk of COVID-19. Monoclonal antibodies …
[HTML] europepmc.org

[HTML][HTML] AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans

Y Loo, PM McTamney, RH Arends, RA Gasser… - 2021 - europepmc.org
Despite the success of SARS-CoV-2 vaccines, there remains a need for more prevention
and treatment options for individuals remaining at risk of COVID-19. Monoclonal antibodies …

AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans

YM Loo, PM McTamney, RH Arends, RA Gasser Jr… - 2021 - pesquisa.bvsalud.org
AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and
extended half-life in humans | PREPRINT-MEDRXIV loading 1 2 3 +A A -A 3.AZD7442 …